Key Drivers
- Strong FCF
- High leverage
- Tight liquidity
AIAI Summary
HCA remains a fundamentally strong cash‑generating compounder, but the investment case is now materially conditional on the timing/continuity of state supplemental payments and the company's ability to convert resiliency/AI initiatives into recurring cash savings—monitor state payment confirmations and quarterly resiliency savings cadence as the decisive triggers that will determine whether buybacks or deleveraging are sustainable.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong FCF
- •High leverage
- •Tight liquidity
HCA delivers strong margins and cash generation (FCF $7.69B, EBITDA margin ~19–20%, EPS $28.70) but is materially risked by very high debt and negative equity with sub‑1 liquidity, making its credit/solvency profile the key risk to its otherwise attractive operating performance.
Price Behavior
Key Price Behavior Insights:
- •Below last month SMA
- •Oversold momentum
- •Fresh intraday low
HCA is in a short‑term downtrend under its last month SMA (~$527.6) but RSI (~28) is oversold, so watch for a bounce at current support ($493.88–$499–$502) or a breakdown below $493.88 for continuation.
Fresh low printed on 2026-03-20 at $493.88 signaling recent selling pressure
Sentiment & News
Key News Insights:
- •Investor outreach
- •Institutional accumulation
- •AI & demographics
HCA Healthcare's March investor roadshow, favorable analyst scores, institutional buying, AI adoption, demographic tailwinds and ethics recognition together highlight broad investor appeal and recent share momentum.
These developments bolster investor confidence and could sustain share strength as operational tailwinds and governance credibility offset sector policy risks
Similar Companies in Healthcare
Other companies in the same sector with AI ratings